Larry Dumont
Concepts (333)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Blood Preservation | 47 | 2024 | 271 | 11.500 |
Why?
| Blood Platelets | 31 | 2024 | 380 | 9.070 |
Why?
| Platelet Transfusion | 19 | 2023 | 59 | 3.900 |
Why?
| Erythrocytes | 24 | 2022 | 672 | 3.700 |
Why?
| Blood Donors | 13 | 2021 | 96 | 3.210 |
Why?
| Cryopreservation | 11 | 2023 | 97 | 3.110 |
Why?
| Plateletpheresis | 11 | 2024 | 27 | 2.300 |
Why?
| Antibodies, Viral | 9 | 2025 | 601 | 1.670 |
Why?
| Dimethyl Sulfoxide | 3 | 2023 | 41 | 1.270 |
Why?
| Platelet-Rich Plasma | 2 | 2023 | 32 | 1.200 |
Why?
| Plasma | 6 | 2014 | 206 | 1.160 |
Why?
| Antibodies, Neutralizing | 8 | 2025 | 265 | 1.130 |
Why?
| Pharmaceutical Solutions | 4 | 2014 | 14 | 1.100 |
Why?
| Mannitol | 4 | 2014 | 38 | 1.030 |
Why?
| Hydrogen-Ion Concentration | 12 | 2024 | 544 | 1.020 |
Why?
| Membrane Lipids | 3 | 2020 | 91 | 0.990 |
Why?
| Sodium Chloride | 4 | 2014 | 138 | 0.970 |
Why?
| Glucose | 8 | 2017 | 1003 | 0.960 |
Why?
| ABO Blood-Group System | 5 | 2020 | 39 | 0.930 |
Why?
| Blood Component Removal | 5 | 2022 | 26 | 0.920 |
Why?
| Adenine | 4 | 2014 | 256 | 0.880 |
Why?
| Metabolome | 4 | 2020 | 338 | 0.840 |
Why?
| Leukocyte Reduction Procedures | 7 | 2020 | 25 | 0.810 |
Why?
| Erythrocyte Transfusion | 9 | 2021 | 181 | 0.800 |
Why?
| Glycolysis | 5 | 2021 | 311 | 0.720 |
Why?
| Humans | 90 | 2025 | 129650 | 0.710 |
Why?
| Cytoskeleton | 1 | 2022 | 183 | 0.710 |
Why?
| Metformin | 1 | 2024 | 315 | 0.710 |
Why?
| Time Factors | 21 | 2023 | 6556 | 0.700 |
Why?
| Adenosine Triphosphate | 6 | 2015 | 480 | 0.680 |
Why?
| Solutions | 4 | 2014 | 151 | 0.620 |
Why?
| Immunization, Passive | 10 | 2025 | 87 | 0.600 |
Why?
| Hemostasis | 3 | 2021 | 79 | 0.600 |
Why?
| Glutathione | 2 | 2017 | 348 | 0.580 |
Why?
| Erythrocyte Membrane | 2 | 2020 | 49 | 0.580 |
Why?
| Carrier Proteins | 1 | 2022 | 743 | 0.580 |
Why?
| Blood Transfusion, Autologous | 3 | 2020 | 16 | 0.570 |
Why?
| Cold Temperature | 3 | 2020 | 155 | 0.570 |
Why?
| Blood Grouping and Crossmatching | 3 | 2016 | 14 | 0.550 |
Why?
| Metabolomics | 5 | 2021 | 652 | 0.500 |
Why?
| Cell Survival | 10 | 2017 | 1086 | 0.500 |
Why?
| Blood Group Incompatibility | 2 | 2012 | 11 | 0.490 |
Why?
| Leukocytes | 3 | 2023 | 304 | 0.480 |
Why?
| Dexamethasone | 1 | 2017 | 346 | 0.480 |
Why?
| Phosphatidylserines | 2 | 2014 | 88 | 0.460 |
Why?
| Cell-Derived Microparticles | 2 | 2018 | 67 | 0.460 |
Why?
| Drug Delivery Systems | 1 | 2017 | 336 | 0.450 |
Why?
| Blood Safety | 3 | 2016 | 10 | 0.430 |
Why?
| Carbon Dioxide | 1 | 2015 | 260 | 0.420 |
Why?
| Transfusion Reaction | 3 | 2022 | 43 | 0.410 |
Why?
| Erythrocyte Aggregation | 1 | 2012 | 3 | 0.410 |
Why?
| Oxidative Stress | 5 | 2020 | 1269 | 0.400 |
Why?
| Blood Proteins | 1 | 2014 | 242 | 0.400 |
Why?
| Citrates | 4 | 2017 | 42 | 0.400 |
Why?
| Dicarboxylic Acids | 1 | 2011 | 6 | 0.380 |
Why?
| Polyvinyl Chloride | 1 | 2011 | 8 | 0.380 |
Why?
| Diethylhexyl Phthalate | 1 | 2011 | 15 | 0.380 |
Why?
| Cyclohexanecarboxylic Acids | 1 | 2011 | 22 | 0.380 |
Why?
| Bacteriological Techniques | 2 | 2013 | 69 | 0.380 |
Why?
| United States Food and Drug Administration | 3 | 2016 | 204 | 0.370 |
Why?
| Catheterization, Peripheral | 1 | 2012 | 104 | 0.370 |
Why?
| Randomized Controlled Trials as Topic | 4 | 2023 | 1368 | 0.360 |
Why?
| Rejuvenation | 1 | 2011 | 18 | 0.350 |
Why?
| Urinary Tract Infections | 1 | 2012 | 152 | 0.350 |
Why?
| Energy Metabolism | 2 | 2021 | 874 | 0.350 |
Why?
| Minerals | 1 | 2011 | 41 | 0.350 |
Why?
| Platelet Aggregation | 3 | 2022 | 95 | 0.350 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 573 | 0.350 |
Why?
| Interferon Type I | 2 | 2021 | 139 | 0.340 |
Why?
| Bacteremia | 1 | 2012 | 197 | 0.340 |
Why?
| Evidence-Based Practice | 1 | 2012 | 212 | 0.340 |
Why?
| Staphylococcus epidermidis | 1 | 2010 | 75 | 0.340 |
Why?
| Oxygen | 3 | 2015 | 915 | 0.330 |
Why?
| Testosterone | 3 | 2022 | 372 | 0.310 |
Why?
| Anaerobiosis | 4 | 2015 | 57 | 0.310 |
Why?
| Thrombocytopenia | 2 | 2022 | 186 | 0.300 |
Why?
| Hemostatics | 2 | 2021 | 49 | 0.300 |
Why?
| Citric Acid | 3 | 2012 | 30 | 0.290 |
Why?
| Platelet Activation | 2 | 2024 | 91 | 0.270 |
Why?
| Bacteria | 2 | 2013 | 821 | 0.270 |
Why?
| Seroepidemiologic Studies | 3 | 2021 | 156 | 0.270 |
Why?
| In Vitro Techniques | 4 | 2021 | 1085 | 0.260 |
Why?
| Leukapheresis | 1 | 2006 | 21 | 0.260 |
Why?
| Blood Transfusion | 4 | 2016 | 296 | 0.260 |
Why?
| Specimen Handling | 1 | 2007 | 164 | 0.260 |
Why?
| Blood Banks | 4 | 2020 | 40 | 0.260 |
Why?
| Hemolysis | 6 | 2020 | 199 | 0.250 |
Why?
| Photopheresis | 2 | 2018 | 9 | 0.250 |
Why?
| Staphylococcal Infections | 1 | 2010 | 393 | 0.250 |
Why?
| Platelet Function Tests | 2 | 2022 | 25 | 0.250 |
Why?
| Lactic Acid | 2 | 2024 | 303 | 0.250 |
Why?
| Adenosine Diphosphate | 2 | 2022 | 80 | 0.240 |
Why?
| Temperature | 3 | 2014 | 636 | 0.240 |
Why?
| Anticoagulants | 4 | 2014 | 637 | 0.240 |
Why?
| Blood Coagulation Tests | 2 | 2015 | 60 | 0.240 |
Why?
| Serologic Tests | 2 | 2022 | 52 | 0.230 |
Why?
| Platelet Count | 4 | 2020 | 82 | 0.230 |
Why?
| Oxygen Consumption | 2 | 2024 | 672 | 0.230 |
Why?
| Male | 25 | 2025 | 63681 | 0.220 |
Why?
| Leukocytes, Mononuclear | 2 | 2023 | 545 | 0.220 |
Why?
| 2,3-Diphosphoglycerate | 2 | 2015 | 32 | 0.210 |
Why?
| Hemoglobins | 4 | 2022 | 339 | 0.210 |
Why?
| Autoantibodies | 2 | 2021 | 1466 | 0.210 |
Why?
| Xenon | 1 | 2022 | 7 | 0.200 |
Why?
| Furocoumarins | 1 | 2022 | 8 | 0.200 |
Why?
| Neuroacanthocytosis | 1 | 2022 | 5 | 0.200 |
Why?
| Refrigeration | 1 | 2022 | 11 | 0.200 |
Why?
| Hormone Replacement Therapy | 2 | 2021 | 92 | 0.200 |
Why?
| Adult | 16 | 2023 | 35576 | 0.200 |
Why?
| HMGB1 Protein | 1 | 2022 | 48 | 0.200 |
Why?
| Granulomatous Disease, Chronic | 1 | 2022 | 53 | 0.200 |
Why?
| Flow Cytometry | 1 | 2006 | 1156 | 0.200 |
Why?
| Hospital Distribution Systems | 1 | 2021 | 1 | 0.190 |
Why?
| Aged | 13 | 2025 | 22103 | 0.190 |
Why?
| Compassionate Use Trials | 1 | 2021 | 7 | 0.190 |
Why?
| Female | 20 | 2025 | 68776 | 0.190 |
Why?
| Radioisotopes | 3 | 2008 | 31 | 0.180 |
Why?
| Middle Aged | 14 | 2025 | 31154 | 0.180 |
Why?
| Bone Marrow Transplantation | 1 | 2022 | 274 | 0.180 |
Why?
| Healthy Volunteers | 2 | 2021 | 200 | 0.180 |
Why?
| Adolescent | 8 | 2021 | 20393 | 0.170 |
Why?
| Nonprescription Drugs | 1 | 2021 | 66 | 0.170 |
Why?
| Organ Preservation Solutions | 2 | 2012 | 45 | 0.170 |
Why?
| Taurine | 1 | 2020 | 43 | 0.170 |
Why?
| Health Services Needs and Demand | 1 | 2021 | 264 | 0.160 |
Why?
| Antibodies, Monoclonal | 2 | 2016 | 1367 | 0.160 |
Why?
| Feasibility Studies | 1 | 2023 | 868 | 0.160 |
Why?
| Prescription Drugs | 1 | 2021 | 112 | 0.160 |
Why?
| Cooperative Behavior | 3 | 2012 | 433 | 0.160 |
Why?
| Cryoprotective Agents | 2 | 2018 | 10 | 0.150 |
Why?
| Asparagine | 1 | 2018 | 30 | 0.150 |
Why?
| Freezing | 1 | 2018 | 86 | 0.150 |
Why?
| Cigarette Smoking | 1 | 2020 | 91 | 0.150 |
Why?
| Oxidation-Reduction | 3 | 2021 | 1033 | 0.150 |
Why?
| P-Selectin | 2 | 2012 | 27 | 0.150 |
Why?
| Aspartic Acid | 1 | 2018 | 81 | 0.150 |
Why?
| Aged, 80 and over | 5 | 2021 | 7086 | 0.150 |
Why?
| Product Packaging | 2 | 2011 | 4 | 0.150 |
Why?
| Blood Buffy Coat | 1 | 2018 | 4 | 0.150 |
Why?
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 282 | 0.150 |
Why?
| Host-Pathogen Interactions | 1 | 2021 | 352 | 0.150 |
Why?
| Buffers | 2 | 2014 | 56 | 0.140 |
Why?
| Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 43 | 0.140 |
Why?
| Nicotine | 1 | 2020 | 303 | 0.140 |
Why?
| Pentose Phosphate Pathway | 1 | 2017 | 50 | 0.140 |
Why?
| Chromatography, Liquid | 2 | 2021 | 423 | 0.130 |
Why?
| Immunoglobulin G | 1 | 2021 | 847 | 0.130 |
Why?
| Dithiothreitol | 1 | 2016 | 17 | 0.130 |
Why?
| Histocompatibility Testing | 1 | 2016 | 120 | 0.130 |
Why?
| Cardiac Surgical Procedures | 1 | 2021 | 499 | 0.130 |
Why?
| Young Adult | 8 | 2021 | 12426 | 0.130 |
Why?
| Government Regulation | 1 | 2016 | 49 | 0.130 |
Why?
| Platelet Adhesiveness | 1 | 2015 | 14 | 0.130 |
Why?
| Severity of Illness Index | 2 | 2021 | 2742 | 0.120 |
Why?
| Protein Processing, Post-Translational | 1 | 2018 | 455 | 0.120 |
Why?
| Transfusion Medicine | 1 | 2015 | 12 | 0.120 |
Why?
| Tandem Mass Spectrometry | 2 | 2021 | 524 | 0.120 |
Why?
| Guidelines as Topic | 2 | 2020 | 264 | 0.120 |
Why?
| Heart-Assist Devices | 1 | 2021 | 539 | 0.120 |
Why?
| False Positive Reactions | 2 | 2016 | 114 | 0.120 |
Why?
| Cross-Over Studies | 3 | 2012 | 521 | 0.120 |
Why?
| United States | 8 | 2021 | 13903 | 0.120 |
Why?
| Monocytes | 1 | 2018 | 551 | 0.120 |
Why?
| Metabolic Networks and Pathways | 1 | 2016 | 178 | 0.120 |
Why?
| Therapeutic Equivalency | 1 | 2014 | 30 | 0.120 |
Why?
| Gases | 1 | 2014 | 44 | 0.110 |
Why?
| Hematocrit | 1 | 2014 | 93 | 0.110 |
Why?
| Osmolar Concentration | 1 | 2014 | 166 | 0.110 |
Why?
| Blood Coagulation Factors | 1 | 2014 | 53 | 0.110 |
Why?
| False Negative Reactions | 2 | 2011 | 53 | 0.110 |
Why?
| Hemorrhage | 1 | 2018 | 678 | 0.110 |
Why?
| Registries | 1 | 2021 | 1896 | 0.110 |
Why?
| Blood Coagulation | 1 | 2015 | 238 | 0.110 |
Why?
| Colony Count, Microbial | 2 | 2011 | 118 | 0.110 |
Why?
| Disease Progression | 1 | 2021 | 2635 | 0.110 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 131 | 0.110 |
Why?
| Hematologic Neoplasms | 2 | 2018 | 140 | 0.100 |
Why?
| Vaccination | 1 | 2021 | 1348 | 0.100 |
Why?
| Treatment Outcome | 6 | 2025 | 10230 | 0.100 |
Why?
| Phosphoric Acids | 1 | 2012 | 17 | 0.100 |
Why?
| Single-Blind Method | 3 | 2021 | 271 | 0.100 |
Why?
| Microscopy, Electron, Transmission | 1 | 2012 | 146 | 0.100 |
Why?
| Checklist | 1 | 2012 | 94 | 0.090 |
Why?
| Nitrogen Mustard Compounds | 1 | 2011 | 6 | 0.090 |
Why?
| Bacteria, Aerobic | 1 | 2011 | 7 | 0.090 |
Why?
| Acridines | 1 | 2011 | 7 | 0.090 |
Why?
| Delphi Technique | 1 | 2012 | 225 | 0.090 |
Why?
| Bacteria, Anaerobic | 1 | 2011 | 23 | 0.090 |
Why?
| Immunity, Humoral | 2 | 2023 | 118 | 0.090 |
Why?
| Klebsiella oxytoca | 1 | 2010 | 2 | 0.090 |
Why?
| Viridans Streptococci | 1 | 2010 | 6 | 0.090 |
Why?
| Heparin | 1 | 2012 | 253 | 0.090 |
Why?
| Serratia Infections | 1 | 2010 | 7 | 0.090 |
Why?
| Preservatives, Pharmaceutical | 1 | 2011 | 26 | 0.090 |
Why?
| Serratia marcescens | 1 | 2010 | 14 | 0.090 |
Why?
| Adaptive Immunity | 2 | 2023 | 161 | 0.090 |
Why?
| Klebsiella Infections | 1 | 2010 | 25 | 0.090 |
Why?
| Sensitivity and Specificity | 2 | 2022 | 1838 | 0.090 |
Why?
| Obesity | 2 | 2020 | 2883 | 0.090 |
Why?
| Graft vs Host Disease | 1 | 2012 | 241 | 0.090 |
Why?
| Kinetics | 1 | 2014 | 1642 | 0.080 |
Why?
| Cell Membrane | 1 | 2014 | 732 | 0.080 |
Why?
| Escherichia coli Infections | 1 | 2010 | 112 | 0.080 |
Why?
| RNA, Viral | 2 | 2025 | 619 | 0.080 |
Why?
| Lipids | 1 | 2014 | 625 | 0.080 |
Why?
| Erythrocyte Count | 2 | 2007 | 19 | 0.080 |
Why?
| Mice | 5 | 2021 | 16937 | 0.080 |
Why?
| Regression Analysis | 1 | 2012 | 993 | 0.080 |
Why?
| Drug Combinations | 1 | 2011 | 330 | 0.080 |
Why?
| Hospitalization | 3 | 2025 | 2070 | 0.080 |
Why?
| Consensus | 1 | 2012 | 616 | 0.080 |
Why?
| Biopsy, Fine-Needle | 1 | 2009 | 68 | 0.080 |
Why?
| Analysis of Variance | 1 | 2012 | 1288 | 0.080 |
Why?
| Thrombosis | 1 | 2012 | 343 | 0.080 |
Why?
| Leukocyte Count | 2 | 2007 | 326 | 0.080 |
Why?
| Thyroid Nodule | 1 | 2009 | 55 | 0.080 |
Why?
| Genetic Heterogeneity | 1 | 2009 | 58 | 0.080 |
Why?
| Publishing | 1 | 2010 | 140 | 0.080 |
Why?
| Safety Management | 1 | 2009 | 112 | 0.080 |
Why?
| Streptococcal Infections | 1 | 2010 | 148 | 0.080 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 5440 | 0.070 |
Why?
| Proteome | 1 | 2012 | 443 | 0.070 |
Why?
| Ultraviolet Rays | 2 | 2022 | 383 | 0.070 |
Why?
| Transportation | 1 | 2007 | 50 | 0.070 |
Why?
| Animals | 6 | 2022 | 35361 | 0.070 |
Why?
| Escherichia coli | 1 | 2010 | 774 | 0.070 |
Why?
| Staphylococcus aureus | 1 | 2010 | 438 | 0.060 |
Why?
| Cell Separation | 1 | 2007 | 316 | 0.060 |
Why?
| Research Design | 1 | 2012 | 1044 | 0.060 |
Why?
| Survival Analysis | 1 | 2009 | 1274 | 0.060 |
Why?
| Risk Assessment | 2 | 2012 | 3240 | 0.060 |
Why?
| Practice Guidelines as Topic | 1 | 2012 | 1501 | 0.060 |
Why?
| Pregnancy | 1 | 2017 | 6402 | 0.060 |
Why?
| Prevalence | 2 | 2021 | 2564 | 0.050 |
Why?
| Genotype | 1 | 2009 | 1839 | 0.050 |
Why?
| Quality Control | 2 | 2016 | 163 | 0.050 |
Why?
| Neutralization Tests | 1 | 2023 | 73 | 0.050 |
Why?
| Clinical Trials as Topic | 1 | 2008 | 1004 | 0.050 |
Why?
| Blood Gas Analysis | 1 | 2003 | 71 | 0.050 |
Why?
| CD40 Ligand | 1 | 2022 | 38 | 0.050 |
Why?
| Retrospective Studies | 4 | 2020 | 14518 | 0.050 |
Why?
| Blood Cell Count | 1 | 2002 | 52 | 0.050 |
Why?
| Prospective Studies | 3 | 2022 | 7133 | 0.050 |
Why?
| Glycerol | 1 | 2022 | 91 | 0.050 |
Why?
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 108 | 0.050 |
Why?
| Masculinity | 1 | 2021 | 8 | 0.050 |
Why?
| Macaca mulatta | 1 | 2022 | 149 | 0.050 |
Why?
| Thrombin | 1 | 2022 | 146 | 0.050 |
Why?
| Convalescence | 1 | 2021 | 18 | 0.050 |
Why?
| Ranitidine | 1 | 2021 | 14 | 0.050 |
Why?
| Public Health Surveillance | 1 | 2021 | 68 | 0.050 |
Why?
| Medically Underserved Area | 1 | 2021 | 84 | 0.050 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2021 | 42 | 0.040 |
Why?
| Hematologic Tests | 1 | 2020 | 21 | 0.040 |
Why?
| Osmotic Pressure | 1 | 2020 | 35 | 0.040 |
Why?
| Ferritins | 1 | 2020 | 58 | 0.040 |
Why?
| Coronavirus | 1 | 2021 | 43 | 0.040 |
Why?
| Infusions, Intravenous | 1 | 2021 | 400 | 0.040 |
Why?
| Double-Blind Method | 1 | 2025 | 1876 | 0.040 |
Why?
| Software | 1 | 2005 | 608 | 0.040 |
Why?
| Signal Transduction | 1 | 2014 | 4925 | 0.040 |
Why?
| Treatment Failure | 1 | 2021 | 340 | 0.040 |
Why?
| Polycythemia | 1 | 2020 | 22 | 0.040 |
Why?
| Outpatients | 1 | 2023 | 370 | 0.040 |
Why?
| Graft Survival | 1 | 2002 | 512 | 0.040 |
Why?
| Hypogonadism | 1 | 2020 | 84 | 0.040 |
Why?
| High-Throughput Screening Assays | 1 | 2021 | 138 | 0.040 |
Why?
| Estradiol | 1 | 2022 | 494 | 0.040 |
Why?
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2018 | 3 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2020 | 588 | 0.040 |
Why?
| Patient Safety | 1 | 2021 | 287 | 0.040 |
Why?
| Methoxsalen | 1 | 2018 | 4 | 0.040 |
Why?
| Health Care Surveys | 1 | 2020 | 559 | 0.040 |
Why?
| Tissue Donors | 1 | 2021 | 391 | 0.040 |
Why?
| Phytohemagglutinins | 1 | 2018 | 28 | 0.040 |
Why?
| Annexin A5 | 1 | 2018 | 23 | 0.040 |
Why?
| Developing Countries | 1 | 2020 | 287 | 0.040 |
Why?
| Child | 3 | 2022 | 20883 | 0.040 |
Why?
| Methylation | 1 | 2018 | 230 | 0.040 |
Why?
| Child, Preschool | 2 | 2022 | 10517 | 0.040 |
Why?
| Inpatients | 1 | 2021 | 467 | 0.040 |
Why?
| Thrombelastography | 1 | 2018 | 150 | 0.030 |
Why?
| Cytokines | 1 | 2025 | 2017 | 0.030 |
Why?
| Methods | 1 | 2016 | 64 | 0.030 |
Why?
| ADP-ribosyl Cyclase 1 | 1 | 2016 | 37 | 0.030 |
Why?
| Cross Reactions | 1 | 2016 | 132 | 0.030 |
Why?
| Antiviral Agents | 1 | 2022 | 712 | 0.030 |
Why?
| Logistic Models | 1 | 2021 | 1988 | 0.030 |
Why?
| Erythrocyte Deformability | 1 | 2015 | 15 | 0.030 |
Why?
| Hemorheology | 1 | 2015 | 21 | 0.030 |
Why?
| Machine Learning | 1 | 2021 | 443 | 0.030 |
Why?
| Blotting, Western | 1 | 2018 | 1205 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2020 | 1214 | 0.030 |
Why?
| Biochemistry | 1 | 2015 | 38 | 0.030 |
Why?
| Immunoglobulins, Intravenous | 1 | 2016 | 130 | 0.030 |
Why?
| Mice, Inbred Strains | 1 | 2016 | 406 | 0.030 |
Why?
| Nitric Oxide | 1 | 2020 | 902 | 0.030 |
Why?
| Chromium Radioisotopes | 1 | 2014 | 4 | 0.030 |
Why?
| Perfusion | 1 | 2015 | 197 | 0.030 |
Why?
| Species Specificity | 1 | 2016 | 575 | 0.030 |
Why?
| Antibodies | 1 | 2016 | 398 | 0.030 |
Why?
| Genetic Association Studies | 1 | 2016 | 360 | 0.030 |
Why?
| Mice, Knockout | 1 | 2021 | 2871 | 0.030 |
Why?
| Bacterial Infections | 1 | 2016 | 237 | 0.030 |
Why?
| Veterans | 1 | 2025 | 1398 | 0.030 |
Why?
| Models, Biological | 1 | 2021 | 1722 | 0.030 |
Why?
| Models, Theoretical | 2 | 2009 | 547 | 0.030 |
Why?
| Pandemics | 1 | 2021 | 1488 | 0.030 |
Why?
| Case-Control Studies | 1 | 2020 | 3381 | 0.020 |
Why?
| Antioxidants | 1 | 2016 | 559 | 0.020 |
Why?
| Body Mass Index | 1 | 2020 | 2273 | 0.020 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 110 | 0.020 |
Why?
| Proteomics | 1 | 2018 | 1062 | 0.020 |
Why?
| Hospitals | 1 | 2016 | 637 | 0.020 |
Why?
| Emergency Service, Hospital | 1 | 2021 | 1902 | 0.020 |
Why?
| Cell Proliferation | 1 | 2018 | 2391 | 0.020 |
Why?
| Cells, Cultured | 1 | 2018 | 4083 | 0.020 |
Why?
| Biomarkers | 1 | 2021 | 3973 | 0.020 |
Why?
| Drug Therapy, Combination | 1 | 2012 | 1040 | 0.020 |
Why?
| Apoptosis | 1 | 2018 | 2503 | 0.020 |
Why?
| Diphosphoglyceric Acids | 1 | 2008 | 4 | 0.020 |
Why?
| Alkalies | 1 | 2008 | 8 | 0.020 |
Why?
| Aerobiosis | 1 | 2008 | 22 | 0.020 |
Why?
| Risk Factors | 1 | 2021 | 9765 | 0.020 |
Why?
| Automation | 1 | 2007 | 82 | 0.020 |
Why?
| Odds Ratio | 1 | 2009 | 1023 | 0.020 |
Why?
| Equipment Design | 1 | 2007 | 514 | 0.020 |
Why?
| Acute Lung Injury | 1 | 2009 | 279 | 0.020 |
Why?
| Evaluation Studies as Topic | 1 | 2005 | 173 | 0.010 |
Why?
| Computer Simulation | 1 | 2009 | 943 | 0.010 |
Why?
| Pilot Projects | 1 | 2008 | 1587 | 0.010 |
Why?
| Sepsis | 1 | 2009 | 574 | 0.010 |
Why?
| Cohort Studies | 1 | 2009 | 5420 | 0.010 |
Why?
|
|
Dumont's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|